Document:

EX-10.32

 Exhibit 10.32 

Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats
as private or confidential. [***] indicates that information has been omitted. 
 FIRST AMENDMENT TO CONTRIBUTION AND LICENSE
AGREEMENT FOR PHARMACEUTICAL FOU 
 This First Amendment to the Contribution and License Agreement for Pharmaceutical FOU (this
“First Amendment’) dated February 28, 2018 is by and between The Invention Science Fund I, L.L.C. (“ISF1”), a Delaware limited liability company, and Pear Therapeutics, Inc.
(“Licensee”, and with ISF1, the “Parties”), a Delaware corporation. 
 RECITALS 

WHEREAS, the Parties entered into the Contribution and License Agreement for Pharmaceutical FOU with an Agreement Date of
February 6, 2015 (the “License Agreement’); and 
 WHEREAS, the Parties wish to amend the License
Agreement to, among other things, revise the applicable field of use and the manner in which royalty payments are determined to facilitate sublicenses that are remunerative to both Parties. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual agreements and covenants set forth in the License Agreement
and this First Amendment, the Parties have agreed as follows: 
 1. AMENDMENTS 

 

	1.1	 All capitalized terms not otherwise defined or amended by this First Amendment shall have the meanings ascribed
to them in the License Agreement. Section of 1 of the License Agreement entitled “Definitions” is hereby amended as follows: 

(a) The definition of “Field of Use” or “FOU” is hereby amended in its entirety to read as follows: 

“POU’’ means the Exclusive Field of Use and the Non-Exclusive Field of
Use. 
 (b) The following five definitions are added: 

“AAA Rules” means the then current Commercial Arbitration Rules and Mediation Procedures (Including Procedures for
Large, Complex Commercial Disputes) of the American Arbitration Association. 
 “Excluded Field of Use” means
(i) the combination of one or more dietary supplements (including vitamins, nutraceuticals, food, dietary minerals, proteins, amino acids and essential fatty acids) and software for treating an indication or side effect, which combination does
not include a Drug, provided, however, use by a consumer of software not marketed, sold or available for sale in combination with a dietary supplement is not within the Excluded Field of Use, or (ii) software marketed, labeled, or
sold for use in combination with a non-prescription dietary supplement. 

 “Exclusive Field of Use” means (i) the combination of a Drug
for treating an indication and software for treating such indication, (ii) software prescribed by a health care provider for treating an indication, or (iii) software prescribed by a health care provider for addressing a side effect of a
Drug, but in each case excluding the Non-Exclusive Field of Use and the Excluded Field of Use. 

“New License Agreement’ shall have the meaning set forth in Section 2.2(b). 

“Non-Exclusive Field of Use” means (a) with respect to Licensee, software
marketed, sold or available for sale without a prescription for health and wellness applications and (b) with respect to an Authorized Sublicensee, software sold or licensed to such Authorized Sublicensee by Licensee that is marketed, sold or
available for sale without a prescription for health and wellness applications, but in each case excluding the Excluded Field of Use.” 

“Royalty Guidance” shall have the meaning set forth in Section 2.2(b)(vi). 

“Royalty Mechanism Dispute” shall have the meaning set forth in Section 11.S(b). 

“Sublicense Fee” means at the election of Licensee on a Licensed Product-by-Licensed Product basis, either 
 (a) a royalty of [***] of Sublicensee Net Revenue or

 (b) the greater of 

(i) a royalty of [***] on the total of the payments invoiced (or otherwise due) by Licensee and/or its Affiliates to
Sublicensee or Sublicensee’s Affiliates for the use, sale, lease, distribution or other disposition of Licensed Products or Revenue Products, or any combination thereof, (provided that with respect to Licensed Products or Revenue Products that
require regulatory approval only amounts invoiced with respect to such Licensed Products or Revenue Products that have obtained regulatory approval shall be included), less the sum of the following actual and customary deductions where applicable
and separately listed, and paid by Licensee or its Affiliates: sales, use, tariff, import/export duties or other excise taxes imposed on particular sales (including value-added taxes but not income taxes imposed on the sales of Licensed Product or
Revenue Product in foreign countries) and 
 (ii) the sum of (x) [***] of Sublicensee Net Revenue that is not attributable to
Combination Products and, (y) [***] of the Total Consideration of Sublicensee and its Affiliates for Combination Products. 
  

	1.2	 Section of 2 of the License Agreement entitled “Licensing” is hereby amended as
follows: 

 (a) Section 2.1 in the License Agreement is hereby amended and restated in its entirety as follows: 

  
 2 

 “2.1 License. Subject to compliance with the terms and conditions of this
Agreement including, without limitation Section 4, ISF1 hereby grants Licensee commencing on the Closing Date an exclusive worldwide, sublicensable (to the extent permitted under Section 2.2), perpetual license, subject to all Encumbrances
under the Licensed Patents to research, develop, make, have made, use, sell, offer to sell, import, export, or distribute Licensed Products solely within or for use within the FOU. The License shall be exclusive in the Exclusive Field of Use (even
as to ISF1, subject to the pre-existing internal research license to ISF1 and its Affiliates) and shall be non-exclusive in the Non-Exclusive Field of Use.” 

(b) Section 2.2 in the License Agreement is hereby amended and restated in its entirety as follows: 

“2.2 Sublicensing. 

(a) The License is sublicensable by Licensee (or by Authorized Sublicensees, as provided below) or their respective Affiliates subject to
compliance with Section 4 and under a sublicense agreement that (i) is as protective of ISF1 as this Agreement, (ii) does not obligate_ISF1 to any further obligation not expressly contained in this Agreement, and (iii) is expressly
limited to the FOU. For clarity, all such sublicense agreements must permit Licensee to audit the books and records of any Sublicensee under terms substantially similar to Section 4.8, and Licensee agrees that Licensee will perform any such
audit upon request by ISF1 or an ISF1 Affiliate. “Authorized Sublicensee” shall mean (a) a direct Sublicensee of Licensee or its Affiliate, or (b) any further sublicensee approved by ISF1 in advance; provided, however,
that ISF1 shall not unreasonably withhold such approval. 
 (b) If this Agreement is terminated by ISF1 pursuant to Section 8.2, 8.3(i),
8.3(ii), 8.3(iii), 8.3(iv), 8.6, or 8.8(i), and an Authorized Sublicensee is not, at the time of such termination, in breach of its obligations to Licensee under the applicable Sublicense, then upon written request by such Authorized Sublicensee,
which request shall be provided to ISF1 no later than thirty (30) days following Authorized Sublicensee’ s receipt of a termination notice from Licensee (a copy of which will be provided to ISF1 by Licensee), ISF1 will grant to such
Authorized Sublicensee a direct license under the Licensed Patents that are sublicensed to such Authorized Sublicensee (the “New License Agreement”) subject to the following terms: 

(i) the New License Agreement (A) must be as protective of ISF1 as this Agreement, (B) must not obligate ISF1 to any further obligation
not expressly contained in this Agreement, and (C) must be expressly limited to the FOU; 
 (ii) the New License Agreement will have
effect as of the date of the termination of this Agreement; 
 (iii) the grant of rights with respect to the Licensed Patents set forth in
the New License Agreement, subject to clause (i) of this Section 2.2(b), will provide for the same grant of rights (including scope of exclusivity and territory) as the grant of rights by the Licensee to the Authorized Sublicensee in the
relevant Sublicense; 

  
 3 

 (iv) the royalties due under the New License Agreement with respect to a Licensed Product or
Revenue Product that do not include, either directly or indirectly, a Drug component (i.e., is not a Combination Product) will be [***] of Net Revenue, wherein the Authorized Sublicensee will be substituted for the Licensee in the definition of Net
Revenue; 
 (v) the royalties due under the New License Agreement with respect to a Combination Product that is being sold by such Authorized
Sublicensee pursuant to the applicable Sublicense prior to the date of such termination of the Agreement will be determined using the same calculation used to determine the royalties owed by Licensee to ISF1 on such Combination Product under
Section 4.1a or 4.1b, as applicable, immediately prior to such termination of the Agreement; and 
 (vi) the royalties due under the New
License Agreement with respect to a Combination Product that is not yet being sold by such Authorized Sublicensee pursuant to the applicable Sublicense on the date of such termination of the Agreement will be subject to the good faith negotiations
of ISF1 and the Authorized Sublicensee giving due consideration to (A) the allocation methodology provided in the applicable Sublicense with respect to the Drug and software components of the Combination Product and (B) the amounts ISF1
would have received from Licensee as the Sublicense Fee on sales by Sublicensee of such Combination Product had the Agreement not been terminated ((A) and (B) are collectively referred to as the “Royalty Guidance”). ISF1
and the Authorized Sublicensee shall initiate such good faith negotiations at least six (6) months prior to Authorized Sublicensee’s commercial launch date for the applicable Combination Product. IfISF1 and the Authorized Sublicensee are
not able to reach agreement within ninety (90) days following the initiation of such good faith negotiations, the parties will resolve the matter according to the arbitration mechanism set forth in Section 11.5(b). 

 

	1.3	 Section of 4 of the License Agreement entitled “Royalties and Payments” is hereby
amended as follows: 

 (a) Section of 4.1a of the License Agreement entitled “Revenue Royalty on Sales Without
Drugs” is hereby amended and restated in its entirety as follows: 
 “4.1a Revenue Royalty on Sales Without Drugs. In
the event that Licensee, a Sublicensee, or one or more of their Affiliates, as applicable, sells a Licensed Product that is not part of a Combination Product, or sells a Combination Product for which it does not pay, reimburse, rebate, or provide
other consideration for the cost of the Drug component of such Combination Product to a third party, Licensee will pay (i) on sales by Licensee and its Affiliates, a royalty of [***] of Net Revenue and (ii) on sales by Sublicensee and its
Affiliates, the Sublicense Fee (individually or collectively the “Revenue Royalties”). In all cases the Revenue Royalties are to be paid in U.S. dollars, based on the U.S. dollar value of the Net Revenue, or Sublicense
Revenue as applicable. Revenue Royalties under (i) and (ii) are due in the year they are accrued and payable along with the royalty report pursuant to Section 4.5 irrespective of whether Minimum Royalties are payable for the same period.
For clarity, if Minimum Royalties are due in the same period as Revenue Royalties, the Royalty due in such period will equal (a) the Minimum Royalty if the aggregate of the Revenue Royalty and each Consideration Fee is less than the Minimum
Royalty or (b) the aggregate of the Revenue Royalty and each Consideration Fee if such aggregate amount is greater than the Minimum Royalty.” 

  
 4 

 (b) Section of 4.1b of the License Agreement entitled “Revenue Consideration For
Sales Of Combination Products” is hereby amended and restated in its entirety as follows: 
 4.1 b Revenue Consideration For
Sales Of Combination Products. In the event that Licensee, Sublicensee, or one or more of their Affiliates, sells a Combination Product for which it is obligated to purchase, reimburse, or rebate the cost of Drugs in connection with the direct
or indirect use, sale, license, distribution, or other disposition of such Combination Product, Licensee will select one of the following two options: 

(i). Option 1: 
 For such
Combination Product, Licensee agrees to pay (i) on sales by Licensee to person other than a Sublicensee or Sublicensee Affiliate, a royalty of [***] of the Total Consideration and (ii) on sales by Sublicensee and its
Affiliates, the Sublicense Fee. 
 (ii). Option 2: 

Licensee agrees to pay an annual fee in accordance with the following Consideration Fee Schedule (Table 1) for each such Combination Product
directly or indirectly sold, licensed, distributed or otherwise disposed of by Licensee, a Sublicensee, or their respective Affiliates or agents. 

Table 1. Consideration Fee Schedule 
  

			
	 Total Consideration (in

millions of US$)
	  	Annual Fee (in US$)
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 All Consideration Fees under (i) and (ii) above are due in the year they are accrued and payable along
with the royalty report pursuant to Section 4.5 irrespective of whether Minimum Royalties are payable for the same period. For clarity, if Minimum Royalties are due in the same period as any Consideration Fee, the Royalty due in such period
will equal (a) the Minimum Royalty if the aggregate of the Revenue Royalty and each Consideration Fee is less than the Minimum Royalty or (b) the aggregate of the Revenue Royalty and each Consideration Fee if such aggregate amount is
greater than the Minimum Royalty. 
  

	1.4	 Section of 5.1 of the License Agreement entitled “Terms of the Agreement” is hereby amended
and restated in its entirety as follows: 

  
 5 

 “5.1 Terms of the Agreement or Information Related to Common Stock. Neither
Party shall disclose the terms of this Agreement to any third party, and ISF1 shall not disclose information related to, or received in connection with, the Common Stock ISF1 holds in Licensee, without the prior written consent of the non-disclosing party, except: 
 (a) to attorneys, auditors, banks, current or prospective financing
sources or partners of or other advisors of such party or its Affiliates, provided appropriate and reasonable confidentiality arrangements are established with such parties; 

(b) to such party’s actual or potential investors in or providers of debt financing to such party, or any Sublicensee, or Affiliates of
either party, or any actual or potential investors in such Sublicensee or such Affiliates, provided appropriate and reasonable confidentiality arrangements are established with such Sublicensee, such Affiliates, or such investors; 

(c) as may be necessary in the opinion of legal counsel to comply with the requirements of judicial process, any law, government order, or
regulation, provided that, to the extent permitted by applicable law, the non-disclosing party is given reasonable advance notice of the same (e.g., so as to afford the
non-disclosing party a reasonable opportunity to appear, object and obtain a protective order or other appropriate relief regarding such disclosure); or 

(d) pursuant to prior written agreement between the parties. 

Notwithstanding the foregoing, any party may disclose (i) the existence (but not the terms) of the Agreement to any third party; and
(ii) the scope of the rights granted in the licenses or the Covenant (but not any other terms) to any party under a written agreement with such party requiring such party to maintain the disclosed information confidential. 

 

	1.5	 Section of 7 of the License Agreement entitled “Continuing Obligations” is hereby
amended as follows: 

 (a) Section 7.2 in the License Agreement is hereby amended and restated in its entirety as follows:

 “7.2 Patent Prosecution Rights. ISF1 or an ISF1 Affiliate will, at its expense, prepare, file, prosecute, and maintain the
Licensed Patents in good faith taking into equal account the interests of Licensee and all other Exclusive Licensees, if any. Licensee will, without any further compensation, cooperate fully and comply with all reasonable requests made by ISF1 or
its Affiliates in furtherance of filing, prosecution, or maintenance of any of the Licensed Patents. ISF1 or an ISF1 Affiliate shall give at least thirty (30) days’ prior written notice to Licensee if ISF1 or such ISF1 Affiliate has
decided to abandon its preparation, filing, prosecution or maintenance of any Licensed Patents or any claim thereof (“Abandoned Patent Rights”). In the event that ISF1 or an ISF1 Affiliate decides to abandon such Abandoned Patent
Rights and either there are no Exclusive Licensees of such Abandoned Patent Rights or the claims of such Abandoned Patent Rights are limited to subject matter that is within the Exclusive Field of Use, Licensee shall have the right, but not the
obligation, at Licensee’s discretion, either to (i) 

  
 6 

 
assume the costs ofISF1 or its Affiliate continuing prosecution and maintenance of such Abandoned Patent Rights ifISF1 or its Affiliate is willing to so continue, or (ii) assume direct
control of the preparation, filing, prosecution and maintenance of such Abandoned Patent Rights, at Licensee’s sole expense. If there is any other Exclusive Licensee of the Abandoned Patent Rights, ISF1 may require any claims that constitute
Abandoned Patent Rights to be prosecuted by Licensee to be limited to subject matter that is within the Exclusive Field of Use given the subject matter of the patent application and any licensing obligations ISF1 may have to other parties, by means
of filing one or more continuation applications or other means reasonably acceptable to ISF1’s patent counsel. Subject to the foregoing, ISF1 will have no further obligation under this Section 7.2 or other provisions of this Agreement with
regard to the Abandoned Patent Rights. Any Sublicense granted by Licensee with respect to any Abandoned Patent Rights by ISF1 or an ISF1 Affiliate is not subject to termination or alteration provided such Sublicense was granted prior to any
abandonment. For clarity, this Section 7.2 does not apply to any Licensed Patents that are the subject of an infringement action or validity defense that is subject to Section 7.5.” 

(b) Section 7.4 in the License Agreement is hereby amended and restated in its entirety as follows: 

“7.4 Patent Office and Other Similar Proceedings. ISF1 or an ISF1 Affiliate will promptly infonn Licensee upon becoming aware of
any request for, filing or institution of any proceeding before a patent office, administrative body, or court (to the extent that the court proceeding is initiated as an appeal from the decision of the patent office or other administrative body),
seeking to protest, oppose, cancel, re-examine, declare an interference proceeding, or initiate any other proceeding affecting the scope, ownership, validity, or term of any of the Licensed Patents
(“Proceeding”). ISF1 or an ISF1 Affiliate will have the right, at ISF1’s or such Affiliate’s discretion, to conduct or defend such Proceeding at its sole expense. Licensee will, without any further compensation,
cooperate with any and all reasonable requests by ISF1 or such ISF1 Affiliate relating to any such proceeding including requests to appoint ISF1 or an ISF1 Affiliate, as its authorized representative for the purpose of conducting and defending any
such Proceeding in consultation with Licensee in the FOU. In the event that ISF1 wishes to abandon the conduct or defense of such Proceeding, and there are no other Exclusive Licensees, and the Licensed Patents or claims thereof are limited to
subject matter that is within the Exclusive Field of Use, Licensee shall have the right, but not the obligation, at Licensee’s discretion, either to (i) assume the costs of ISF1 or its Affiliate continuing to conduct or defend such
Proceeding, if ISF1 or its Affiliate is willing to so continue, or (ii) assume direct control and defense of such Proceeding, at Licensee’s sole expense For clarity, no infringement actions or validity defenses subject to Section 7.5
are subject to this Section 7.4.” 
 (c) Section 7.5 in the License Agreement is hereby amended and restated in its entirety as
follows: 

  
 7 

 “7.5 Enforcement and Defense. Each party will promptly give the other party
notice upon becoming aware of any instance of infringement of any Licensed Patents in the Exclusive Field of Use (“Notice of Infringement”). If the infringing activity is solely within the Exclusive Field of Use and there are no
Exclusive Licensees of the infringed Licensed Patents, Licensee shall have the first right, at its discretion, but not the obligation, to initiate, direct and settle any infringement action or validity defense relating to such infringement of the
Licensed Patents (“Litigation”), at its own expense and by counsel of its own choice, and ISF1 shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If ISF1 does not elect to be
represented in such Litigation, Licensee shall reimburse ISF1 for all reasonable and customary costs and expenses incurred by ISF1 in cooperating with any reasonable requests made by Licensee including being joined to the Litigation proceeding. In
all other cases of infringement of the Licensed Patents, ISF1 shall have the first right, at its discretion, but not the obligation, to initiate, direct and settle any Litigation, provided that any settlement agreement granting rights under the
Licensed Patents within the Exclusive Field of Use requires Licensee’s prior written consent (not to be unreasonably withheld, delayed or conditioned by Licensee), and, to the extent such infringement is in the Exclusive Field of Use, Licensee
shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. All Litigation by either party under this Section 7.5 shall be subject to the following: 

(a) The party having the first right to initiate, direct and settle any Litigation with respect to infringement of the Licensed Patents under
this Section 7.5 (the “First Right Party”) will provide the other party with written notice as to whether or not it intends to initiate such Litigation (“Initiation Notice”) within ninety (90) days
following Notice of Infringement, and, if ISF1 is the First Right Party, that Initiation Notice will include ISF1’s good faith estimate of the expense of such Litigation. 

(b) If Licensee is the First Right Party with respect to any infringement of the Licensed Patents, and Licensee either notifies ISF1 within
such 90-day period that Licensee does not intend to initiate Litigation with respect to such infringement, or Licensee fails to provide any Initiation Notice to ISF1 within such
90-day period, then ISF1 shall have the right, at its discretion, but not the obligation, to initiate, direct and settle Litigation with respect to such infringement at ISF1’s expense, provided that any
settlement agreement granting rights under the Licensed Patents within the Exclusive Field of Use requires Licensee’s prior written consent (not to be unreasonably withheld, delayed or conditioned by Licensee), and Licensee shall not share in
any recovery from such Litigation. 
 (c) If (A) ISF1 is the First Right Party with respect to any infringement of the Licensed Patents,
(B) the infringing activity is both within and outside of the Exclusive Field of Use, and (C) ISF1’s Initiation Notice specifies that ISF1 intends to initiate Litigation, then, except as set forth in Section 7.5(d), such expenses
shall be equitably allocated among such fields of use outside of the Exclusive Field of Use and the Exclusive Field of Use, by reasonable agreement between ISF l, all Exclusive Licensees and Licensee (“Expense Allocation”). If ISF1,
any Exclusive Licensee and Licensee are unable to reach agreement concerning the Expense Allocation within thirty (30) days of the Initiation Notice, ISF1 shall reasonably and in good faith allocate such expenses equitably taking into equal
account the reasonable interests of Licensee, each Exclusive Licensee and ISF1, provided that in no event shall Licensee’s Expense Allocation exceed [***] without the express written consent of Licensee. If Licensee agrees in writing to

  
 8 

 
pay its share of the expenses as allocated in this Section 7.5(c) within forty (40) days of the Initiation Notice, ISF1 will pennit Licensee to defer reimbursement for the
Licensee’s allocation of expenses. Subject to Section 7.5(f), in no event may such deferment be later than sixty (60) days after the final adjudication, entry of a settlement agreement or dismissal of the Litigation. In addition, if
the actual expenses of such Litigation exceed [***] of ISF1’s good faith estimate of such expenses as set forth in its Initiation Notice, Licensee shall not be obligated to pay more than its Expense Allocation on [***] of ISF1’s good faith
estimate. 
 (d) IfISF1 is theFirst Right Party and Licensee gives notice to ISF1 within forty (40) days of the Initiation Notice that
Licensee declines to fund Licensee’s allocated share of expenses of the Litigation, then (i) Licensee will not be obligated to pay the expenses of such Litigation, and (ii) Licensee shall not share in any recovery. 

(e) IfISF1 is theFirst Right Party, ISF1 will carry out its obligations under the preceding portions of this Section 7.5 in an efficient
and cost-effective manner. Licensee will, without any further compensation but with its reasonable out-of-pocket expenses reimbursed (except as set forth in
Section 7.5(f)), cooperate fully with any and all reasonable requests by ISF1 relating to any such Litigation including being joined in any such Litigation proceeding. If ISF1 elects not to initiate, or after initiation elects not to continue,
Litigation proceedings in respect of an allegation of infringement or to conduct a defense in respect of a Licensed Patent’s validity or enforceability, ISF1 will, within a reasonable period of time following its decision, inform Licensee of
its election. Thereafter, if Licensee elects to have the right, at its own expense to initiate, conduct or settle such action or conduct such defense, it shall inform ISF1 of the same by written notice provided, however, that Licensee shall not have
such rights unless and until consented to by ISF1 and all other Exclusive Licensees, if any, in writing. 
 (f) Any money recovered by
Licensee as a result of any Litigation under this Section 7.5 with respect to which it is the First Right Party, or with respect to which ISF1 was the First Right Party but elected not to initiate or continue Litigation, will be distributed first to
reimburse Licensee’ s and ISF1’s direct, reasonable, documented expenses actually incurred (and not previously reimbursed), and then any remaining balance shall be allocated to Licensee and be treated as Net Revenue for purposes of
Section 4. la in the quarter in which it is received. Any money recovered by ISF1 as a result of any Litigation under this Section 7.5 which Licensee helps to fund will be distributed first to reimburse ISF1’s, Licensee’ s and
any other Exclusive Licensee’s direct, reasonable, documented expenses actually incurred (although ISF1 will not receive reimbursement under this sentence of any such expenses already reimbursed to ISF1 by Licensee pursuant to this
Section 7.5), and then any remaining balance shall be allocated pro rata to ISF1, Licensee and any other participating Exclusive Licensee in the same proportion as such entity’s contribution to the aggregate expenses of bringing and
conducting the proceeding and settlement under this Section 7.5.” 
  

	1.6	 Section of 8.8 of the License Agreement entitled “Termination for Failure to Operate in the
FOU’ is hereby amended and restated in its entirety as follows: 

  
 9 

 “8.8 Termination for Failure to Operate in the FOU. 

(i) “Failure to Operate” shall mean a failure of Licensee, an Authorized Sublicensee and their Affiliates, following
commercial launch of a Licensed Product or Revenue Product, to sell or offer for sale at least one Licensed Product or Revenue Product in the Exclusive Field of Use for a period of at least one (1) year, subject to tolling in respect of
regulatory barriers to sale outside of Licensee’ s control. 
 (ii) In the event of a Failure to Operate pursuant to
Section 8.8(i), and subject to Section 8.9 hereof, this Agreement and all licenses and other rights granted under the Agreement shall terminate pursuant to Section 8.3(iv).” 

 

	1.7	 Section of 11.5 of the License Agreement entitled “Applicable Law and Venue” is hereby
amended and restated in its entirety as follows: 

 “11.5 Applicable Law and Venue. 

(a) The validity, construction and performance of this Agreement will be governed by and construed in accordance with the laws of the State of
Delaware, without regard to the principles of conflict oflaws. Each Party hereto irrevocably consents to binding arbitration in a neutral jurisdiction in connection with any matter based upon or arising out of this Agreement or the matters
contemplated herein. 
 (b) Notwithstanding Section 11.5(a), if ISF1 and the Authorized Sublicensee are unable to reach agreement within
the ninety (90) day negotiation time period set forth in Section 2.2(b)(vi) (“Royalty Mechanism Dispute”) and such Authorized Sublicensee agrees to resolve such Royalty Mechanism Dispute in accordance with this
Section 11.5(b), ISF1 and the Authorized Sublicensee will submit the Royalty Mechanism Dispute to mediation and, if necessary, arbitration pursuant to the following provisions: 

(i) Such persons will jointly appoint a mutually acceptable mediator and agree to participate in good faith in a mediation session that shall
occur within thirty (30) days from the Royalty Mechanism Dispute or such extended period agreed to by such persons in writing. If the mediation does not result in a resolution within thirty (30) days after the mediation session, such
persons will resolve the Royalty Mechanism Dispute by final and binding arbitration conducted in English by one arbitrator reasonably familiar with patent valuation and licensing, which arbitration will occur in Bellevue, Washington, U.S.A. in
accordance with the then-current AAA Rules as modified by this Section 11.5(b). The arbitrator will be selected by mutual agreement of such persons or, failing such agreement, in accordance with the AAA Rules. 

(ii) Each of such persons will submit to the arbitrator and exchange with the other its best offer, which best offers will provide, to the
extent possible, reasonable support for the basis and amounts included in such proposed method for determining the applicable amounts contemplated by Section 2.2(b)(vi). In the event the arbitrator requests more information than the information
included in the best offers, ISF1 or the Authorized Sublicensee (as applicable) will provide the arbitrator and the other person such additional information as the arbitrator requests. The arbitrator shall be limited to selecting one of the two
positions submitted, which selection will take into account the Royalty Guidance and shall be final and binding upon such persons. 

  
 10 

 (iii) Each of such persons will bear its own attorney fees, and all other costs of any
mediation and/or arbitration will be borne by such persons equally. 
 2. MISCELLANEOUS 

 

	2.1	 All other terms and conditions of the License Agreement shall remain the same and shall remain in full force
and effect. The provisions set forth in Section 11 of the License Agreement (except as amended herein) shall apply to this First Amendment. 

  

	2.2	 This First Amendment may be executed in counterparts, each of which shall be deemed an original but all of
which shall constitute one and the same instrument. 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused
this First Amendment to be executed by their respective authorized representatives. 
  

									
	ISF1:	 		  	LICENSEE:
	The Invention Science Fund I, L.L.C.	 		  	Pear Therapeutics, Inc.
					
	By:	 	 /s/ Clarence Tegreene
	 		  	By:	  	 /s/ Corey McCann

	Name: Clarence Tegreene	 		  	Name: Corey McCann
	Title: EVP	 		  	Title: Chief Executive Officer

  
 11EX-10.33

 Exhibit 10.33 

Certain identified information has been omitted from this exhibit because it is 

not material and of the type that the registrant treats as private or confidential. 

[***] indicates that information has been omitted. 

SECOND AMENDED AND RESTATED SOFTWARE LICENSE AGREEMENT 

THIS SECOND AMENDED AND RESTATED SOFTWARE LICENSE AGREEMENT (the “Agreement”) is made as of July 1, 2021(the
“Second Amended and Restated Effective Date”) by and between Pear Therapeutics, Inc. (“Pear”), a Delaware corporation having its principal place of business at 200 State
Street, 13th Floor, Boston MA 02109, and Red 5 Group, LLC (“Licensor”), a New York limited liability company, having its principal place of business at 15 Grant Road,
Hanover, NH 03755. The definitions appear in Exhibit A attached hereto. 
 WHEREAS Licensor owns and operates a software application
called Therapeutic Education System (TES) which is used for the treatment of psychological and substance-use disorders, as described more fully in Exhibit B (the “Application”);

 WHEREAS, Licensor licenses the Application in the form of a software development kit (“SDK”). The SDK is a
customized version of the Application, which includes clinical data tables, software, source code, all applicable intellectual property, know-how, clinical data, and sample user interface modules, as well as
the necessary hooks to communicate Pear Data to agreed-upon third parties. (The SDK, Content, and the Application, collectively, the “Licensor Products”); 

WHEREAS, Pear and Licensor entered into a Software License Agreement (the “Original Agreement”) dated as of
January 9, 2015 (the “Effective Date”), under which Pear received a license to access and use the Licensor Products in order to allow Pear to embed a customized version of the Licensor Products into its own software and
content offerings (i.e., the Pear Application) in order to create Integrated Products for use by healthcare professionals and patients worldwide; 

WHEREAS, Pear and Licensor entered into an Amended and Restated Software License Agreement (the “Amended and Restated
Agreement”) dated as of March 21, 2018 to expand the scope of the exclusive license granted under the Original Agreement and to otherwise amend the Original Agreement as set forth therein, and subsequently entered Amendment
No. 1 to the Amended and Restated Agreement dated as of April 19, 2018; and 
 WHEREAS, Pear and Licensor now desire to amend and
restate, as of the Second Amended and Restated Effective Date, the Amended and Restated Agreement, as amended by Amendment No. 1, upon the terms and conditions set forth below. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as
follows: 
 Pear Confidential 

 1. DEFINITIONS. 

Capitalized terms used but not defined in the body of this Agreement are used with the meanings ascribed to them in Exhibit A. The
meanings given to terms in this Agreement are equally applicable to both the singular and the plural forms of the terms as the context may require. 
 2.
LICENSE. 
 2.1 Grant of Licenses. Subject to the terms of this Agreement, including payment of the Fees set forth in Section 5, Licensor
hereby grants Pear a worldwide, royalty-bearing, non-transferable (except as permitted in the Agreement) right and license, with the right of sublicense (through multiple tiers), under the Licensor IP: 

2.1.1 to use, modify, reproduce, display, distribute and create derivative works of the Content to create Integrated Products in all fields of use and to
promote, commercialize and fully exploit such Integrated Products; 
 2.1.2 to use, copy, distribute and modify the
non-Content components of Licensor Products in order to create Integrated Products. The Integrated Products may be offered as part of a comprehensive offering which may include, without limitation, compliance
software, medical support, and data outcomes monitoring, separately created by Pear or others; 
 2.1.3 to re-brand
the Application and the other components of the Licensor Products with marks of Pear’s choosing when used as part of the Integrated Products, provided that Licensor is clearly identified as creator of the Application and Content (e.g.,
“powered by Red5Group” or comparable ingredient branding agreed upon by the parties); 
 2.1.4 to distribute and sublicense the Integrated Products
to its Users and for such Users to access and use the Content as part of the Integrated Products. Pear’s license rights in this Section 2.1 include the right for Pear to provide access to the Integrated Products to its Users directly or
indirectly through Pear’s Distributors, OEMs and resellers; and 
 2.1.5 to use the Integrated Products in clinical validation studies. 

2.1.6 The license rights granted above to Pear by Licensor will be exclusive (including as to Licensor). Licensor has no right to use or license the Content or
the non-Content components of Licensor Products for any purpose (including without limitation as stand-alone materials or as integrated with any other products); provided that Licensor may continue to use the
Licensor Products solely for the purpose of completing its obligations to provide support to the following academic studies: (1) A sequenced behavioral and medication intervention for cocaine dependence (Grant#: 1R01DA034087;
Funder: NIDA); (2) Web-based addiction treatment: Cultural adaptation with American Indians (Grant# R34DA040831; Funder: NIDA); (3) The social interactome of recovery: Social media as therapeutic
development. (Grant#: R01DA039456; Funder NIDA); and (4) a study being performed by the Virginia Department of Corrections pursuant to a grant from the Edward Byrne Memorial Justice Assistance Grant Program (Byrne/JAG). Pear will not
be under any obligation to use the Licensor Products and/or the Content in any manner whatsoever unless it so chooses. 

  
 2 

 2.2 Restrictions. Except as expressly permitted in this Agreement, Pear will not (and will not permit
third parties to): 
 (a) distribute, rent, or otherwise transfer any rights in the Licensor Products in any way except as part of an
Integrated Product (i.e., Pear may not distribute the Licensor Products on a standalone basis; 
 (b) except as necessary in the creation of
Integrated Products, modify the Application; 
 (c) except as necessary in the creation of Integrated Products, reverse engineer, decrypt,
decompile, or disassemble the Licensor Products; or 
 (d) use the Licensor Products in any manner or for any purpose not authorized by
Section 2.1. 
 2.3 Sublicensees. The right of Pear to grant sublicenses is subject to the requirement that each such sublicense shall be in
writing and shall be subject to the applicable license(s) and rights granted hereunder, including all restrictions set forth herein, including Section 2.1 of this Agreement and Sections 1.1, 2, 4.1(b), and 5 of Exhibit C to this Agreement. Pear
shall at all times remain responsible for the performance of any of its sublicensees. 
 3. RESPONSIBILITIES OF THE PARTIES. 

3.1 Responsibilities of Licensor. Licensor will have primary responsibility for performing the following tasks and providing the following services:

 3.1.1 Delivery. Licensor will deliver the Licensor Products in the manner set forth in Exhibit B. Unless otherwise specified in Exhibit
B, Licensor will deliver all Licensor Products electronically to the location(s) designated by Pear. Licensor will deliver patches, updates, and upgrades to the Licensor Products in accordance with the terms set forth in Exhibit B. 

3.1.2 Integration. Licensor will work with Pear (for a mutually agreed upon duration of at least 60 days and not more than 1 year), to integrate the
Licensor Products with a Pear Application; both parties will work in good faith to ensure that the integration will not materially adversely impact the core functionality of the Application. 

3.1.3 Clinical validation. Licensor will provide Pear with access to all newly created clinical data involving the Application as well as, where
feasible, access to all existing clinical data involving the Application. Upon request and subject to mutually agreeable terms with respect to time and payment, Licensor may assist Pear in the design for clinical validation studies, including the
composition of grant applications for clinical validation studies. Costs associated with these activities shall be covered by Pear at reasonable rates to be agreed by both parties. 

3.1.4 Reserved. 
 3.1.5 Additional Services. Licensor shall
provide any other services reasonably requested by Pear subject to the parties entering into an agreement on mutually acceptable terms. Without limiting the generality of the foregoing, and by way of illustration, Licensor will commit on a case by
case basis, to provide support for partnership discussions with branded or generic pharmaceutical companies, pharmacy chains, or other with potential distribution partners for Integrated Products, with the number of hours, rates and fees to be
mutually agreed by the parties in writing as an addendum to this Agreement, prior to the commencement of any such work. 

  
 3 

 3.2 Responsibilities of Pear. 

3.2.1 Data provided to Licensor. Subject to the Confidentiality provisions in Exhibit C, Pear will provide Licensor with access to any
evaluations, methodology and the data produced through use of the Integrated Products that Pear’s partners/licensor allow Pear to access and provide (collectively, “Product Data”); provided that, Licensor may only use such Product
Data for Licensor’s internal research purposes only. Without limiting the generality of the foregoing, and by way of illustration, (a) Licensor may not use any Product Data to target market any end users on behalf of a competitive product
or services; (b) the Product Data will not contain any personally identifiable information; and (c) such Product Data will be owned by Pear. 

3.2.2 Third Party Partnerships. Subject to any applicable confidentiality obligations that may apply, Pear will provide a summary of material terms of
any distribution or other licensing agreements with third parties for the Integrated Products prior to entering into any such agreements. 
 3.3 Mutual
Obligations of the Parties. Pear will respond to any support requests arising from Users that relate specifically to the Pear Customizations or any Pear functionality or data contained in the Integrated Product. Licensor will provide Pear (but
not customers) with high level telephone and email support regarding any and all technical issues arising from the Licensor Products themselves that Pear is unable to resolve; these support services will be delivered in accordance with
Licensor’s standard support practices for this level of support. 
 4. HIPAA REQUIREMENTS. 

4.1 Compliance with HIPAA. Licensor acknowledges that any Pear Data transmitted to Licensor hereunder may be subject to federal and state laws, rules
and regulations relating to among other subjects, the confidentiality, privacy or security of patient information, including without limitation, the Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act
of 1996, Public Law 104-191.45 C.F.R. Part 160, 162, 164 (“HIPAA”) and the applicable regulations promulgated thereunder. The parties will at all times comply with the applicable
provisions of such laws, rules, and regulations and with the applicable corporate policies and provision of the parties, with respect to the performance of their obligations under this Agreement, with respect to the confidentiality, privacy and
security of Protected Health Information (“PHI”) and electronic Protected Health Information, as defined in 45 C.F.R. § 164.501 (“ePHI”). For purposes of this Agreement, PHI means individually
identifiable information as defined by the Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. Parts 160 and 164. 

  
 4 

 5. FEES. 

5.1 License Fees. Pear will pay Licensor the license fees set forth in Exhibit B (the “License Fee”). The License Fees
authorize Pear and its Users to access the Integrated Products for the period identified in Exhibit B (the “License Term”). 

5.2 Reimbursement of Expenses. Pear will reimburse Licensor for all reasonable
out-of-pocket expenses incurred by Licensor in performing services under this Agreement provided such expenses are approved in writing by Pear in advance. Such out-of-pocket expenses may include: (a) All reasonable travel expenses, other than for normal commuting, including airfares, rental vehicles, and highway mileage in
company or personal vehicles at the then current IRS approved rate, and meals and lodging; and (b) All other reasonable expenses resulting from the Services provided under this Agreement, as applicable. Licensor shall submit an itemized
statement of Licensor’s expenses due under this Section 5.2, including receipts and other documentation, on a monthly basis. Pear shall reimburse Licensor within thirty (30) days from the receipt of each statement by Pear. 

6. STANDARD LEGAL TERMS AND CONDITIONS: The Standard Legal Terms and Conditions governing this Agreement are contained in Exhibit C and
incorporated herein by reference 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Second Amended and
Restated Effective Date. 
  

			
	PEAR THERAPEUTICS, INC.:	  	Red 5 Group, LLC:
		
	By: /s/ Christopher
Guiffre                                        
            	  	By: /s/ Michael Grabinski                            
		
	Name: Christopher D.T. Guiffre	  	Name: Michael Grabinski
		
	Title: Chief Financial Officer & Chief Operating Officer	  	Title: President
	Date: 7/2/2021	  	Date: 7/2/2021

  
 5 

 EXHIBIT A 

DEFINITIONS 
 “Affiliate”
means with respect to either party, any Person that, directly or indirectly, is controlled by, controls or is under common control with such party. For purposes of this Agreement, “control” means, with respect to any Person, the
direct or indirect ownership of more than fifty percent (50%) of the voting or income interest in such Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person. 

“Application” has the meaning set forth in the first Recital to the Agreement, and as further described in Exhibit B. 

“Confidential Information” means any and all information disclosed or made available by either party to the other, including orally
conveyed information, in connection with this Agreement that is: (a) at the time of disclosure identified or marked as confidential or proprietary information; or (b) by its nature and the circumstances should be considered, or is
reasonably obvious to be confidential information. Confidential Information shall be deemed to include the Pear Data, if any, supplied by Pear to Licensor pursuant to this Agreement. Confidential Information does not include any information that the
receiving party can demonstrate is: (a) rightfully known prior to disclosure; (b) rightfully obtained from a third party authorized to make such a disclosure, without breach of the terms and conditions of this Agreement or other binding
confidentiality obligation; (c) independently developed by the receiving party; (d) available to the public without restrictions; (e) approved for disclosure with the prior written approval of the disclosing party; or
(f) disclosed by court order or as otherwise required by law, provided that the party required to disclose the information provides prompt advance notice to enable the other party to seek a protective order or otherwise prevent such disclosure.

 “Content” means audio and visual information, source code, documents, software, products and services contained in the
Application or made available to Pear, including any and all updates and improvements thereto made prior to the Amended and Restated Effective Date, and source code alterations made by or on behalf of Licensor during the licensing period. 

“Distributor” means a third party distributor or agent that is not a sublicensee, that Pear,
an Affiliate or a sublicensee utilize for purposes of Integrated Product distribution in a particular country(ies). A Distributor places orders for Integrated Products (or services provided through the use of Integrated Products) from Pear or its
Affiliates or sublicensees for distribution to customers in the applicable country(ies); a Distributor does not itself hold rights to make, have made or use Integrated Products (or services provided through the use of Integrated Products), but may
hold the right to resell the units of, or in the case of software, provide access to, such Integrated Products (or services provided through the use of Integrated Products) it acquires from Pear, an Affiliate or a sublicensee to Users in the
applicable country(ies). 
 “Integrated Product” means the product resulting from the integration of the Licensor Product with a
Pear Application. The Integrated Product will constitute a “Wrapper for Pear or its sublicensee/third party” –i.e., a customized version of the Application for use by Pear and its Users, with compliance and other layers and allow
Users to access software functionality and other data and content contained in the Licensor Products, and will be hosted on servers owned and/or controlled by Pear. 

 “License Term” means the period identified in Exhibit B for which Pear will
have access to the Licensor Products. 
 “Licensor IP” means collectively, the Licensor Products made available to Pear by Licensor
under the Agreement, including any source code, know-how, and clinical data related to the Application, and all trademarks licensed by Licensor to Pear under the Agreement. 

“Licensor Products” has the meaning set forth in the second Recital to the Agreement, and is as further described in Exhibit B.

 “Pear Application” means the portions of any Integrated Product that are created by Pear. 

“Pear Customizations” means any proprietary scripts, macros, modules or software developed by Pear or Licensor to customize
Pear’s use of, or access to, the Licensor Products as part of Integrated Products. 
 “Pear Data” means any data, information
or material that Pear and/or Pear’s Users submit to or receive from the Integrated Products, as well as all clinical data from clinical studies involving any Pear resources. 

“Pear IP” means collectively, the Integrated Products (excluding the portions that constitute Licensor IP); the Pear Application; the
Pear Customizations; the Pear Data; Pear trademarks; and the Pear-Owned Property, as well as any and all improvements to IP, improvements to source code. 

“Pear-Owned Property” means all tangible and intangible items or information that Licensor receives from Pear or from a third party on
Pear’s behalf, or that is paid for by Pear, including but not limited to Pear Data and Pear Customizations. 
 “Person” means
any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision
thereof) or other legal entity or organization, other than Pear or Licensor. 
 “Users” means the users of the Integrated Products.

 EXHIBIT B – LICENSE SCHEDULE 

LICENSE TERMS AND FEES 

This License Schedule sets forth the terms and conditions for a license for the use of the Licensor Products, as identified below. Except as
expressly modified by this License Schedule, the terms and conditions of the Agreement govern the license to the Licensor Products. 
  

	 	(1)	 LICENSE TERM. 

The license term begins on the Effective Date and will continue, unless sooner terminated in accordance with the Agreement, in perpetuity. 

 

	 	(2)	 DESCRIPTION OF LICENSOR PRODUCTS. 

The Licensor Products include the following software modules. For the avoidance of doubt, Licensor does not withhold access to any therapeutic
treatment modules used in TES research studies, whether listed below or not. 
 T E S Module List 

Training Module 
 This module
describes the purpose of TES and teaches new users how to use TES. 
 What is a Functional Analysis? 

This module explains the purpose of a functional analysis of recent drug use (to identify the various risk factor(s) for the drug use, and
the consequences of the drug use). 
 Conducting a Functional Analysis 

This module walks the TES user through the process of a personalized functional analysis of their last drug use. 

Introduction to Problem Solving 

This module explains the importance of learning to effectively identify, analyze, and solve problems. 

Effective Problem Solving 
 This
module teaches the importance of effective problem solving and teaches several steps to effective problem solving. 
 Self-Management Planning

 This module teaches strategies one can use to manage high-risk situations for drug use. 

Drug Refusal Skills 
 This
module teaches the importance of learning effective strategies for refusing drug offers and teaches several such strategies. 

 Identifying and Managing Triggers for Risky Drug Use 

This module defines what “triggers” are, how they can influence behavior choices around drug use, and how to manage those triggers
in order to reduce risk. 
 Managing Thoughts About Using 

This module is designed to teach one to identify thoughts or feelings that can lead to using drugs, and ways he or she could manage these
thoughts or feelings to prevent drug use. 
 Coping with Thoughts About Using 

This module teaches several actions one can take to effectively cope with thoughts about using drugs. 

Seemingly Irrelevant Decisions 

This module teaches individuals how everyday decisions, which may appear to have nothing to do with drug use, may actually lead one closer
to being faced with a choice about drug use if not handled effectively. 
 Decision-making Skills 

This module includes text about the different steps of making decisions and highlights the importance of giving yourself adequate time to make
the best possible decision. 
 Increasing self-confidence in decision-making 

This module discusses one’s personal values and goals and describes situational self-confidence. 

HIV and AIDS 
 This module
outlines basic information about transmission and prevention of HIV, the difference between HIV and AIDS, treatment and HIV testing. 
 Sexually
transmitted infections (STIs) 
 This module defines sexually transmitted infections (STIs) generally, and describes several of
the more prevalent STIs including transmission, treatment, and prevention. 
 Hepatitis 

This module outlines basic information about hepatitis A, B and C including transmission and prevention. 

Sexual transmission of HIV and STIs 

This module includes discusses the types of sexual activity that pose risk, and prevention options for each type of risky sexual activity. 

Selecting and correctly using condoms 

This module describes the different types of condoms and lubricant, which are considered effective and which are not, and how to use condoms
correctly. 

  
 9 

 The Female Condom 

This module describes the use of the female condom in more depth, including graphics depicting the steps to using the female condom. 

Birth control use and HIV and STIs 

This module discusses how most contraceptive methods do not offer any protection against HIV and STIs, and addresses the need to consider the
possibility of both pregnancy and HIV/STIs when considering sexual activity. 
 Drug Use, HIV & Hepatitis 

This module teaches information about how the use of different drugs and different drug paraphernalia directly increases risk for HIV and
hepatitis and techniques for reducing the risk of viral infection through drug use and equipment. 
 Alcohol use and risk for HIV, STIs and hepatitis

 This module discusses the relationship between alcohol use and the way that it influences and potentially changes choices that a
person makes about safety and protection against disease. 
 Getting tested for HIV, STIs and Hepatitis 

This module describes the available options for testing for HIV, STIs and Hepatitis, and what an individual can expect to experience during the
testing process. 
 Identifying & managing triggers for risky sexual activity 

This module defines what triggers are, how they can influence behavior choices around sexual activity, and how to manage those triggers in
order to reduce risk. 
 Social Recreational Counseling 

The goal of this module is to increase user’s participation in social activities that may serve as healthy alternatives to drug use. 

Time Management 
 This module
teaches individuals how to plan and schedule events to engage in activities that provide alternatives to drug use and reduce the amount of idle, high-risk time. 

Communication Skills I Sharing Feelings 

This module discusses the potential benefit of sharing one’s feelings with others. 

Attentive Listening 
 This module
teaches the goals of attentive listening and how to be an attentive listener. 
 Drug Use and Communication Skills 

This module discusses how drug use may impact one’s ability to listen and express oneself. 

Negotiating Safer Sex 
 This module
includes text describing the importance of communications skills in the ability to reduce risk for HIV, hepatitis and STIs, some of the challenges and barriers to communication, and the description of skills that can be used in negotiating safer sex
with a partner. 

  
 10 

 Giving and Receiving Compliments 

This module discusses the importance of giving and receiving compliments in relationships with others and discusses strategies for effectively
doing so. 
 Introduction to Giving Criticism 

This module discusses the importance of providing constructive criticism to others. 

Steps for Giving Constructive Criticism 

This module provides guidelines for effectively giving constructive criticism to others. 

Receiving Criticism 
 This module
discusses the importance of receiving criticism and strategies for effectively doing so. 
 Nonverbal Communication Nonverbal Communication

 This module discusses how nonverbal behavior may greatly affect interactions with others. 

Introduction to Assertiveness 

This module describes various interpersonal styles including the meaning of assertiveness. 

How to Express Oneself in an Assertive Manner 

This module teaches individuals strategies on how to be assertive. 

Introduction to Anger Management 

This module describes the effects of anger and how angry thoughts and feelings may impact behavior. 

How to Become More Aware of the Feeling of Anger 

This module teaches individuals how to recognize feelings of anger they may be experiencing. 

Coping with Anger 
 This module
teaches effective coping strategies for dealing with anger. 
 Introduction to Relaxation Training 

This module teaches the role that relaxation may play in reducing stress. 

Progressive Muscle Relaxation Training 

This module teaches progressive muscle relaxation and breathing techniques. 

Progressive Muscle Relaxation Generalization Training 

This module teaches individuals how to apply relaxation techniques in everyday life. 

  
 11 

 Awareness of Negative Thinking 

This module teaches how thoughts can affect feelings and behaviors and teaches individuals to recognize patterns of negative thinking. 

Managing Negative Thinking 
 This
module teaches strategies for effectively managing negative thoughts. 
 Financial Management 

This module helps individuals understand how to better manage their financial resources in getting more control over their lives. 

Relationship Counseling - Part 1 

This module presents several communication behaviors that one may find useful in improving communication with another person. 

Relationship Counseling - Part 2 

This module teaches strategies one can use to effectively manage disagreements with another person. 

Relationship Counseling - Part 3 

This module teaches skills to effectively resolve arguments with another person. 

Vocational Counseling 
 This module
helps an individual improve their employment situation or locate work and highlights the importance that work can play in helping to prevent drug use. 

Insomnia 
 This module teaches
strategies for helping individuals manage insomnia and sleep better. 
 Living with HIV: Coping skills and managing stigma 

This module describes the challenges of living with HIV and some techniques for coping with the disease and the stigma that can be associated
with it. 
 Living with HIV: Communication skills for disclosing HIV status 

This module discusses the issue of disclosure, the challenges that it presents, and strategies for deciding who and when to tell, and how to
tell others about having HIV. 
 Living with HIV: Managing treatment and medications 

This module describes some of the challenges of maintaining antiretroviral medication regimes including side effects, timing, and cultural and
other barriers to taking medications. It also describes the importance of talking with health care providers about concerns and problems with medications and strategies to overcome some of the challenges. 

Living with HIV: Drug use and the immune system 

This module describes how drug use can impact the immune system of someone with HIV, including how drug use may increase exposure to bacteria
and other viruses that could have an added detrimental effect on the health of someone who has HIV. 

  
 12 

 Living with HIV: Daily routines to promote healthy behavior 

This module describes the importance of daily routines such as a healthy diet, stress reduction, adequate sleep, taking prescribed meds,
reducing or eliminating alcohol and other drug use etc. in maintaining health and managing HIV. 
 Living with Hepatitis C: Coping skills 

This module describes the challenges of living with Hepatitis C and some techniques for coping with the disease. It includes video clips of
people who are living with Hep C and their thoughts on coping. 
 Living with Hepatitis C: Managing treatment and promoting healthy
behavior 
 This module describes the importance of daily routines such as a healthy diet, stress reduction, adequate sleep,
reducing or eliminating alcohol and other drug use etc. in maintaining health and managing Hepatitis C. 
 Alcohol and Disulfiram 

This module describes how disulfiram medication may be useful in preventing alcohol use among individuals with alcohol use disorders. 

Other Drug Abuse 
 This module
discusses how use of drugs other than opioids may increase one’s likelihood of relapsing to opioid use. 
  

	 	(3)	 UPGRADES. 

Licensor shall provide Pear, at no additional cost with all upgrades, updates, bug fixes, improvements, and enhancements to the Licensor
Products that Licensor generally makes available to its customers at no cost (collectively, “Upgrades”). Licensor will provide Pear with the same testing instructions and description of the new functionality or features of all
Upgrades that it provides to its other customers. Any Upgrades shall automatically be included within the definition of Licensor Products. For the avoidance of doubt, Upgrades do not include new Licensor software that has new and different
functionality and performance than the Licensor Products software described in this Exhibit B. 
  

	 	(4)	 FEES. 

(A) License Fees. In connection with the licenses granted in this Agreement, Pear will pay Licensor as follows: 

(i) Royalties. Licensor will be paid a royalty equal to [***] of Net Revenue during the Term following the Second Amended and Restated
Effective Date and a royalty equal to [***] of Net Revenue during the Term prior to the Second Amended and Restated Effective Date. Pear will provide payments to Licensor within sixty (60) days following the calendar
quarter during which Pear records the corresponding Net Revenue; provided, however, in the event Pear should become subject to the Securities Exchange Act of 1934, then Pear will provide payments to Licensor within ten (10) days following
Pear’s quarterly Form 10-Q filing or annual Form 10-K filing for the applicable period; provided such filings are made on a timely basis in accordance with the
applicable provisions of the Securities Exchange Act of 1934. Pear will provide reports 

  
 13 

 
along with license payments hereunder in sufficient detail to illustrate the basis for the payments made, including the number of units of Integrated Products sold (or units of services provided
through the use of Integrated Products), the gross price charged by Pear or its Affiliates for such units, calculation of Net Revenue, including a listing of the deductions taken, the total royalty payable in U.S. Dollars, together with the exchange
rates used for any currency conversion and the number of sublicenses granted. 
 If Pear or any Affiliate sells or leases Integrated Products (or services
provided through the use of Integrated Products) in connection with other products or services for a bundled price, Pear covenants that it shall not, and that it shall cause its Affiliates to not apply any such discount in a manner that is applied
in a manner that has disproportionate effect on the Integrated Products (or services provided through the use of Integrated Products). 

“Net Revenue” means the gross amount invoiced by Pear or its Affiliates to any independent
third party sublicensee, Distributor or any end user for Integrated Products (or services provided through the use of Integrated Products), less: [***]. 

No deductions shall be made for commissions paid to individuals whether they are with independent sales agencies or regularly employed by Pear and on its
payroll, or for cost of collections. 
 For the avoidance of doubt, Net Revenue shall not apply with respect to units of Integrated Products (or services
provided through the use of Integrated Products) that are distributed for clinical study purposes, or for other evaluation or testing purposes that are provided free of charge. Pear will not discriminate against the Integrated Products in a manner
that would disproportionately discount the price of the Integrated Product and thereby reduce the royalties payable to Licensor hereunder as compared with the discount applied to any other products or services offered by Pear to the customer. 

No non-Affiliate sublicensee revenue will be included in Net Revenue. In addition, Net Revenue will be calculated only
once with respect to each unit of Integrated Product (or services provided through the use of Integrated Products) sold by Pear or any Affiliate to any Distributor, non-Affiliate sublicensee or end user, even
if such Integrated Product (or services provided through the use of Integrated Products) is sold more than once in the course of its transfer to the ultimate end-user. For the avoidance of doubt, if there are
sales of Integrated Products between or among Pear and/or any of its Affiliates for the purpose of further resale to non-Affiliated customers, such sales will not be included in the calculation of Net Revenue
(however, the final sale by Pear or an Affiliate to a non-Affiliate sublicensee, Distributor or end user customer will be included in Net Revenue), and payments from licensees relating to events prior to FDA
approval such as sublicense fees and development milestone payments will not be included in the calculation of Net Revenue, provided that the agreements with licensees that include such payments also include a conventional royalty provision. 

  
 14 

 Non-monetary consideration shall not be accepted by Pear or
any Affiliate or sublicensee for any Integrated Products (or services provided through the use of Integrated Products), without the prior written consent of Licensor. In the event that non-monetary
consideration is received for Integrated Products (or services provided through the use of Integrated Products), Net Revenue shall be calculated based on the fair market value of such non-monetary
consideration (including all elements of such consideration), as determined by the parties in good faith. For the avoidance of doubt, it is understood and agreed that non-monetary consideration (e.g., data)
received in the context of clinical validation studies or sponsored research where Integrated Products are not being commercially sold, and any non-monetary consideration (e.g., data) included in a
multifaceted agreement in which the primary form of consideration is monetary, shall not be considered a violation of this clause. 
 If a unit of
Integrated Product (or services provided through the use of Integrated Products) is leased to a Distributor or end user rather than sold to such Distributor or end user, then Net Revenue in respect of such units of Integrated Product (or services
provided through the use of Integrated Products) shall be calculated on an annual basis and shall equal the aggregate lease payments paid by the Distributor or end user for the use of such unit of Integrated Product (or services provided through the
use of Integrated Products). 
 For the avoidance of doubt, and for all purposes under this Agreement Net Revenue, including the deductions specified in
clauses (i)-(iv), shall be calculated in accordance with United States Generally Accepted Accounting Principles (“GAAP”). 
 (ii)
Annual License Maintenance Fee. Pear shall pay to Licensor the following license maintenance fees within 30 days after the dates set forth below: 
  

					
	 Effective Date
	  	$	30,000	 
	 First anniversary of Effective Date
	  	$	35,000	 
	 Second anniversary of Effective Date
	  	$	40,000	 
	 Third anniversary of Effective Date
	  	$	45,000	 
	 Fourth and each subsequent anniversary of the Effective Date (each, an “Annual License
Maintenance Fee”)
	  	 	[***]	 

 This Annual License Maintenance Fee (“ALMF”) is nonrefundable; however, the ALMF may be credited to cumulative
royalties and Milestone payments due under this Agreement, until the full amount that Pear is entitled to deduct from royalties or Milestones payable to Licensor under this Agreement in respect of such ALMF payment is fully deducted as a credit. For
the avoidance of doubt, in no event will Licensor be paid less than the ALMF of [***] in any calendar year after the Second Amended and Restated Effective Date during the term of this Agreement, and the ALMF credit described above may not be applied
as a credit against any subsequent ALMF payment due under this Agreement. [***]. 
 (iii) Milestones. In addition to the above
royalty, milestone payments will be paid as follows; 1) $200,000 paid to Licensor on [***], and 2) $200,000 paid to Licensor on [***]. 

(iv) Inspections. Pear shall maintain, and shall cause its Affiliates and sublicensees to maintain, complete and accurate records
relating to the rights and obligations under this Agreement and any amounts payable to Licensor in relation to this Agreement, which records shall contain sufficient information to permit Licensor to confirm the accuracy of any reports delivered to
Licensor and compliance in other respects with this Agreement. The relevant party 

  
 15 

 
shall retain such records for at least five (5) years following the end of the calendar year to which they pertain, during which time Licensor, or Licensor’s appointed agents, at
Licensor’s reasonable request no more than once per calendar year, shall have the right, at Licensor’s expense, to inspect such records of Pear or its Affiliates during normal business hours to verify any reports and payments made or
compliance in other respects under this Agreement. In the event that any audit performed under this Section 4 reveals an underpayment in excess of five percent (5%), Pear shall bear the full cost of such audit and shall remit any amounts due to
Licensor within thirty (30) days of receiving notice thereof from Licensor. 
 (v) Payment. Beginning on the Second Amended and
Restated Effective Date, unless otherwise agreed in writing by the parties, each payment of any Annual License Maintenance Fee or royalties hereunder will be made by electronic funds transfer with immediately available funds to an account
designated in writing by Licensor to Pear or any such new or additional account(s) Licensor shall designate in writing no later than ten (10) business days prior to the date such Annual License Maintenance Fee payment or
royalty payment is due. Licensor shall invoice Pear for each Annual License Maintenance Fee in accordance with Section 8.2 of Exhibit C. 

(B) Additional Fee for Amending and Restating the Original Agreement. In consideration for expanding the exclusive license under
Section 2.1.1 and otherwise amending and restating the Original Agreement, Pear agreed to pay Licensor a one-time payment in the amount of [***] at the time the parties entered into the Amended and
Restated Agreement. Licensor hereby acknowledges that it has received this one-time payment from Pear. 

(C) Payment of Accrued Fees in Connection with Second Amended and Restated Software License Agreement. Within three (3) business
days following the Second Amended and Restated Effective Date, Pear shall pay Licensor [***]. 
 (D) Refund or Credit for
Overpayments. Pear and Licensor acknowledge and agree that, in the event that Pear notifies Licensor in writing of an overpayment within ninety (90) days of having made such overpayment to Licensor providing the amount of such overpayment
and accounting detail reasonably sufficient to demonstrate such overpayment, Licensor will refund to Pear the amount of such overpayment within ninety (90) days following receipt of such written notice. If Pear notifies Licensor in writing of
an overpayment more than ninety (90) days after having made such overpayment to Licensor providing the amount of such overpayment and accounting detail reasonably sufficient to demonstrate such overpayment, Pear will not be entitled to a refund
of the overpayment amount but will instead be entitled to a credit of the overpayment amount. 
  

	 	(5)	 THIRD PARTY PRODUCTS 

The Licensor Products are configured for operation with certain commonly available off the shelf software products listed below. Pear may
require different third party licenses for Integrated Products depending upon the manner in which they are configured and deployed. 
  

	 	•	 	 MySQL Community Edition 

 

	 	•	 	 Java 8 

  

	 	•	 	 MySQL Connector/J 

  
 16 

	 	•	 	 Apache Commons 

  

	 	•	 	 Apache Tomcat 

  

	 	(6)	 DELIVERY. 

Within 30 days of the Effective Date, Licensor will ship to Pear a digital compact disc containing the Licensor Products. Licensor will make
Upgrades available to Pear on a web site designated by Licensor and accessible using FTP protocols. 

  
 17 

 EXHIBIT C 

STANDARD LEGAL TERMS AND CONDITIONS 
 2.
Ownership. 
 2.1 Title to Licensor Products. Pear acknowledges that title to the Licensor IP made available to Pear by Licensor under this
Agreement is and will remain the sole property of Licensor. Pear acknowledges that it has no proprietary interest in or right to use the Licensor IP or the Licensor Products except in accordance with the terms of the licenses granted in this
Agreement. 
 2.2 Title to Pear IP. Subject to its underlying rights in the Licensor Products, Licensor acknowledges that title to the Pear IP is and
will remain the sole property of Pear. Without limiting the generality of the foregoing and by way of illustration only, Licensor acknowledges that it has no proprietary interest in or right to use the Pear Data or the Pear-Owned Property except in
accordance with the express terms of this Agreement. 
 2.3 Assignment. To the extent that Licensor has or at any time acquires any right, title or
interest in or to any Pear Data, Integrated Products (excluding Licensor Products), Pear Customizations or any other Pear IP, Licensor hereby assigns all of such right, title and interest, including all copyrights, patents and other intellectual
property rights, in and to such Pear IP to Pear. On request from Pear, Licensor shall execute any documents necessary to confirm and perfect Pear’s ownership of the Pear IP, at no additional cost to Pear. 

3. Confidentiality. Neither party will use any Confidential Information of the disclosing party except as expressly permitted in this Agreement or as
expressly authorized in writing by the disclosing party. Each party shall use the same degree of care to protect the disclosing party’s Confidential Information as it uses to protect its own Confidential Information of like nature, but in no
circumstances less than reasonable care. Neither party is allowed to disclose the other party’s Confidential Information to any person or entity other than the receiving party’s officers, employees, consultants and legal advisors who need
access to such Confidential Information to effectuate the intent of the Agreement. Each party agrees to notify the other of any unauthorized use or disclosure of Confidential Information and to provide reasonable assistance to such other party, and
its licensors, in the investigation and prosecution of such unauthorized use or disclosure. 
 4. Warranties. Licensor represents and warrants each of
the following: 
 4.1 Title. Licensor has title or the right to grant licenses to the Application and the Licensor Products in accordance with the
terms of this Agreement and without the obligation to pay third parties in respect of such licenses by Licensor. 
 4.2 Performance. The Application
and Licensor Products, and any Upgrades shall substantially conform to their specifications; provided however, that the foregoing warranty will not apply to the extent the Licensor Products are modified by Pear or used beyond the scope of the
licenses granted in this Agreement. 
 4.3 Reserved. 

 4.4 Other Licenses. The performance of this Agreement and Pear’s use of the Licensor Products
will not require any license to use the intellectual property of a third party, except as otherwise expressly set forth on Exhibit B. If any part of the Licensor Products contains third-party software, Licensor has the full power and authority to
sublicense the third-party software as part of its license grant to Pear. 
 4.5 No Viruses. The Licensor Products will be tested with commercially
available anti-virus software to detect the presence of any viruses, worms, disabling programming codes, instructions or other such items that may threaten, infect, damage, disable or otherwise interfere with the permitted use of the Licensor
Products (“Virus”) and Licensor shall not deliver any Licensor Products to Pear unless the Licensor Products pass such tests. 
 4.6
Malicious Technology. The Licensor Products as delivered to Pear will not: (i) contain any Malicious Technology, (ii) contain any files or features that will disable or destroy any functionality of the Licensor Products,
(iii) monitor Pear’s or its Users’ use of the Integrated Products; (iv) replicate, transmit or activate itself without control of a person operating the computing equipment on which it resides; or (v) alter, damage or erase
any data or computer programs without control of a person operating the computing equipment on which it resides. If the Licensor is in breach of this Section, no “right to cure” period will apply. Pear reserves the right to pursue any
available civil or criminal action against Licensor for violation of this provision. Licensor will not install, use or execute any software on any Pear CPUs without Pear’s written approval. “Malicious Technology” means
any software, electronic, mechanical or other means, device or function, e.g. (key node, lock, time-out, “back door,” trapdoor,” “booby trap,” “drop dead device,”
“data scrambling device,” “Trojan Horse,”) that would allow Licensor to: (i) monitor or gain unauthorized access to any Pear system, (ii) use any electronic self-help mechanism or (iii) restrict, disable, limit or
impair the performance of a Pear system or network. 
 4.7 Compliance with Laws. Licensor will comply with all applicable laws, orders, codes and
regulations in the performance of this Agreement and in its access to and use of Product Data as set forth in Section 3.2.1, including, if applicable, those regarding privacy and security of protected health information. Licensor warrants that
it has not at any time been disbarred or excluded from participation in any federal healthcare program, nor is Licensor under investigation or consideration for such disbarment or exclusion. Licensor will obtain and keep current at its expense all
governmental permits, certificates and licenses (including professional licenses, if applicable) necessary for Licensor to grant the licenses under this Agreement. Licensor will proactively and cooperatively work with and assist Pear in a timely
manner to ensure that the Licensor Products have been effectively tested and complies with all legal requirements prior to or contemporaneously with the effective date of such legal requirements. 

4.8 Good Standing. Licensor (i) is validly existing and in good standing, and is qualified to do business, in each jurisdiction where it will
conduct business under this Agreement; (ii) the signing, delivery and performance of this Agreement by the party has been properly authorized; and (iii) no claims, actions or proceedings are pending or, to the knowledge of the party,
threatened against or affecting the party that may, if adversely determined, reasonably be expected to have a material adverse effect on the party’s ability to perform its obligations under this Agreement. 

 4.9 Open Source. The Licensor Products are not subject to any requirements that would give rise under
applicable open source license agreements to any rights in any third parties with respect to the Licensor Products or any derivative works, or obligations for Pear to disclose or distribute the Integrated Products in source code form, or
conditioning the distribution of Integrated Products on disclosure of any source code, or to license the Integrated Products for the purpose of making derivative works, or to distribute Integrated Products without charge. 

4.10 Breach of Warranty; Remedy. If there is a breach of any warranty, Licensor will promptly replace and/or repair the nonconforming Licensor Products
at Licensor’s sole cost. If Licensor fails to promptly replace and/or repair nonconforming Licensor Products, Pear may, in addition to exercising any other available remedies, replace or repair nonconforming Licensor Products and take as a
credit against payments due Licensor an amount equal to the actual documented costs of such repair or replacement of the Licensor Products (but not costs relating to other components of Integrated Products) or terminate the license at Pear’s
sole discretion and receive a pro-rata refund for any pre-paid fees prior to such date of termination. 

5. Indemnification. 
 5.1 Indemnification. (a) Subject
to the provisions of Section 4.1(c), Licensor shall defend, indemnify and hold harmless Pear and its affiliated entities, and all of their officers, directors, employees, agents, successors and assigns from and against any and all claims,
proceedings, damages, injuries, liabilities, losses, costs and expenses (including reasonable attorney’s fees and litigation expenses) (“Losses”) arising from any third party claim: that the
Licensor Products infringe any intellectual property right of any third person. Licensor shall have no liability or obligation to LICENSEE under this Section 4.1(a) with respect to any infringement claim in the event and to the extent based
upon: (i) use of the Licensor Products in an application or environment or on a platform or with devices for which the Licensor Products was not designed or contemplated; (ii) modifications, alterations or enhancements of the Licensor
Products not created or authorized by Licensor; (iii) any patent, copyright or trademark in which Pear or any Affiliate of Pear has an ownership interest; (iv) the combination of Licensor Products with other software, hardware, products,
processes, methods, or applications not furnished, authorized or contemplated by Licensor; (v) failure of Pear to install Upgrades to the Licensor Products provided by Licensor; or (vi) Pear continuing its infringing activities after being
notified of such infringement by Licensor; in each case of clauses (i) through (vi), where no such claim would have been possible had such activities not taken place. The foregoing indemnification action shall not apply in the event and to the
extent that such Losses arose as a result of any indemnified party’s negligence, intentional misconduct or breach of this Agreement, or is the subject of Section 4.1(b). 

(b) Subject to the provisions of Section 4.1(c), Pear will defend, indemnify and hold harmless Licensor and its affiliated entities, and all of their
officers, directors, employees, agents, successors and assigns from and against any and all Losses arising from any third party claim to the extent arising from or related to: use, sale or other disposition by Pear or by any party acting on behalf
of or under authorization from Pear, of Integrated Products to the extent such Losses are not based on the Licensor Products and are not otherwise subject to indemnification by Licensor under the terms of Section 4.1(a). The foregoing
indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any indemnified party’s negligence, intentional misconduct or breach of this Agreement, or is the subject of Section 4.1(a). 

 (c) To receive indemnification under Section 4.1(a) or Section 4.1(b), the party seeking
indemnification must promptly notify the indemnifying party in writing of a claim or suit and provide total cooperation and immediately tender to the indemnifying party (and its insurer) full authority to defend or settle the claim or suit. The
party seeking indemnification shall cover all costs associated with its defense until the claim is finally resolved at which time the indemnifying party shall reimburse the indemnitee for such costs associated with the prosecution of the claim.
Neither party has any obligation to indemnify the other party in connection with any settlement made without the indemnifying party’s written consent. 

5.2 Disruption of Use of Licensor Products. If a third-party claim subject to indemnification under Section 4.1(a) prevents Pear’s use of the
Licensor Products, Licensor shall, at Licensor’s sole option: (a) replace the Licensor Products, without additional charges, with a functionally equivalent and non-infringing product; or
(b) modify the Licensor Products to avoid the infringement; or (c) obtain a license for the Pear to continue use of the Licensor Products and pay for any additional fee required for such license. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN
THIS AGREEMENT, THE FOREGOING STATES LICENSOR’S ENTIRE LIABILITY AND PEAR’S EXCLUSIVE REMEDY FOR PROPRIETARY RIGHTS INFRINGEMENT. 
 6.
LIMITATION OF LIABILITY. EXCEPT IN THE EVENT OF BREACH OF ITS CONFIDENTIALITY OBLIGATIONS, OR INFRINGEMENT OF THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS, OR INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT WILL EITHER
PARTY BE LIABLE TO THE OTHER FOR ANY INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, OR DAMAGES ON ACCOUNT OF LOSS OF PROFITS OR FAILURE TO ACHIEVE ANTICIPATED REVENUES, EVEN IF SUCH DAMAGES WERE WITHIN THE CONTEMPLATION OF THE PARTIES.
EXCEPT FOR INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT, OR A BREACH OF ITS CONFIDENTIALITY OBLIGATIONS, OR INFRINGEMENT OF THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS, IN NO EVENT WILL EITHER PARTY’S TOTAL AGGREGATE LIABILITY FOR
ALL CLAIMS ARISING OUT OF THIS AGREEMENT EXCEED THE AMOUNT PAID OR PAYABLE BY PEAR UNDER THIS AGREEMENT PRIOR TO THE EFFECTIVE DATE OF THE NOTICE OF ANY SUCH CLAIM. THIS PROVISION APPLIES REGARDLESS OF HOW THE LIABILITY AROSE OR THE THEORY OF
LIABILITY, INCLUDING WITHOUT LIMITATION CONTRACT OR TORT (INCLUDING PRODUCTS LIABILITY, STRICT LIABILITY, NEGLIGENCE AND MISREPRESENTATION). 
 7. Term
And Termination. 
 7.1 Term. The term of this Agreement begins on the Effective Date and will continue for the duration of the License Term (the
“Term”). 
 7.2 Termination for Material Breach. If a party materially breaches this Agreement, the other party must give the breaching
party a material breach notice, identifying the action or inaction that is the basis of the breach. The party giving the breach notice may terminate this Agreement if the other party does not cure the breach to the reasonable satisfaction of the non-breaching party within thirty (30) days after receiving the breach notice. No breach under this Agreement will constitute a breach under any other agreement, license or schedule between the parties. Unless
otherwise provided in the breach notice or unless the breach has been cured to the reasonable satisfaction of the non-breaching party, the termination is effective
thirty-one (31) days after the breach notice is given. 

 7.3 Reserved. 

7.4 Reserved. 
 7.5 Termination Without Cause. Pear may at
any time without cause terminate this Agreement upon at least sixty (60) days written notice to Licensor. 
 7.6 Effect of Termination.
Termination of this Agreement is without prejudice to any other right or remedy of the parties. Termination of this Agreement for any reason does not release either party from any liability which, at the time of termination, has already accrued to
the other party, or which may accrue in respect of any act or omission prior to termination or from any obligation which is expressly stated to survive the termination. 

7.7 Post-Termination Obligations. Upon termination of this Agreement, the parties will perform the following obligations: 

 

	 	(A)	 Within fifteen (15) days after the effective date of termination or expiration, each party will return to
the other party all Confidential Information of the other party in its possession; Licensor will return Pear Owned Property to locations designated by Pear, and Pear will return all Licensor Products in its possession; 

 

	 	(B)	 Within thirty (30) days after the effective date of termination or expiration, Licensor will invoice Pear
for any final amounts accrued prior to the effective date of termination under the Agreement; 

  

	 	(C)	 Within one hundred ninety (190) days after the effective date of termination, Pear will terminate
availability of access to the Integrated Products. The parties will mutually agree on mechanisms for Licensor to monitor such cessation, which may include a license validation system incorporated into the Integrated Product, and the right to monitor
App Store listings; and 

  

	 	(D)	 Both parties will immediately discontinue making any statements or taking any actions that might cause third
parties to infer that a business relationship continues to exist between the parties under the Agreement, and where necessary or advisable, the parties will inform third parties that the parties no longer have a business relationship.

 8. Miscellaneous. 
 8.1
Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Licensor are, and will otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code (the “Bankruptcy
Code”) and other similar foreign laws, licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code or such foreign laws. 

 
The parties agree that Pear will retain and may fully exercise all of its rights and elections under applicable law and under the Bankruptcy Code. 

8.2 Notice. Notices provided under this Agreement must be in writing and delivered by (i) certified mail, return receipt requested, (ii) hand
delivered, (iii) facsimile with receipt of a “Transmission OK” acknowledgment, (iv) e-mail, or (v) delivery by a reputable overnight carrier service (in the case delivery
by facsimile or e-mail the notice must be followed by a copy of the notice being delivered by a means provided in (i), (ii) or (v)). The notice will be deemed given on the day the notice is received. In the
case of notice by facsimile or e-mail, the notice is deemed received at the local time of the receiving machine, and if not received, then the date the follow-up copy is
received. Notices must be delivered to the following addresses or at such other addresses as may be later designated by notice: 
  

			
	Pear:	  	Licensor:
		
	Corey McCann	  	[***]
	200 State Street, 13th Floor	  	[***]
	Boston, MA 02109	  	[***]
	Email: [***]	  	[***]

 8.3 Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto, their successors,
assigns, and legal representatives. Except as otherwise set forth in this Agreement, Pear will not assign any of the licenses granted to it under the Agreement in whole or in part without Licensor’s prior written consent; provided however that
notwithstanding the foregoing, (i) Pear may assign this Agreement to any successor to its business, including by a purchase or sale of all or substantially all of the assets, stock or business operations, any change of control, acquisition,
merger or consolidation of either party into, by, or with another entity, or any other transfer by operation of law (a “Transaction”); and (ii) Pear may hire or contract with third parties of its choice to assist it in fulfilling its
obligations and exercising any of its rights pursuant to this Agreement, provided that Pear will remain liable for the subcontractor’s performance. 

8.4 Access to Books and Records. To the extent that Section 952 of P.L. 96-499 (42 U.S.C.
Section 1395x(v)(1)) is applicable to this Agreement, the parties agree as follows: (a) until the expiration of four (4) years after the furnishing of such services pursuant to this Agreement, each party shall make available, upon
written request of the Secretary of the U.S. Department of Health and Human Services or upon request of the Comptroller General of the United States, or any of his/her duly authorized representatives, this Agreement, and books, documents and records
of such party that are necessary to certify the nature of the duties of this Agreement; and (b) if either party performs its services hereunder through a subcontract with a value of cost of Ten Thousand Dollars ($10,000) or more over a twelve
(12)-month period, then any such subcontract shall contain a clause to the effect that until the expiration of four (4) years after the furnishing of such services pursuant to such subcontract, the related organization shall make available,
upon written request of the Secretary of the U.S. Department of Health and Human Services or upon request of the Comptroller General of the United States, or any of his/her duly authorized representatives, the subcontract, and books, documents and
records of such organization that are necessary to verify the nature and extent of the cost of services provided pursuant to such subcontract. 

 8.5 Governing Law. This Agreement shall be governed, interpreted and enforced under and in accordance
with the laws of Delaware, excluding its conflicts of law provisions. Each party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the
transactions contemplated hereby. 
 8.6 Unenforceability. Should any of the parties’ obligations under this Agreement be found illegal or
unenforceable in any respect, such illegality or unenforceability shall not affect the other provisions of the Agreement, all of which shall remain enforceable in accordance with their terms. Any unenforceable provisions shall be replaced by an
enforceable provision effecting the intention of the parties, as determined by the tribunal of fact. 
 8.7 Currency. All amounts are stated and
payable in United States dollars. 
 8.8 Survival. The following sections of the main body of the Agreement and of this Exhibit C will survive
expiration or termination of this Agreement for any reason: Section 4 of the main body of the Agreement (“HIPAA Requirements”); and Sections 1 (“Ownership”), 2 (“Confidentiality”), 3 (“Warranties”), 4
(“Indemnification”); 5 (Limitation of Liability); 6.6 (“Effect of Termination”), 6.7 (“Post-Termination Obligations”), and 7 (Miscellaneous) of this Exhibit C. 

8.9 Use of Name. Nothing in this Agreement grants Licensor the right to use any trademarks, trade names or logos proprietary to Pear. If Licensor is
granted a right to use such marks, Licensor will do so only in strict compliance with Pear guidelines provided by Pear. All goodwill associated with any use of Pear trademarks will inure to Pear. 

8.10 Remedies. All rights and remedies of the parties, under this Agreement, in law or at equity, are cumulative and may be exercised concurrently or
separately. The exercise of one remedy will not be an election of that remedy to the exclusion of other remedies. 
 8.11 Applicability of Laws. Each
party will comply with all applicable export laws, obtain any applicable export licenses and will not export or re-export any part of the Licensor Products to any country in violation of such restrictions, or
any country that may be subject to an embargo by the United States. 
 8.12 Public Announcements. Neither party will make any public announcement
regarding the business relationship of the parties or this Agreement without the other party’s prior express written permission, unless required by law; in which case, the disclosing party will provide the other party as much advance written
notice as reasonably possible. Notwithstanding the foregoing, Pear will be entitled, without Licensor’s prior consent, to publicly disclose the existence of the licensee/licensor relationship under this Agreement, but not the specific
commercial terms of the Agreement. 
 8.13 Entire Agreement. This Agreement, including Exhibits, all of which are attached, constitute the entire
Agreement and understanding between Licensor and Pear concerning the subject matter hereof, and supersedes and terminates all prior written and oral agreements, proposals, promises, and representations of the parties respecting the subject matter of
this Agreement. In the event of any conflict or ambiguity between any Exhibit and the terms and conditions set forth in this Agreement, the terms and conditions in this Agreement shall control.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]